Screening of blood donations for the presence of antibodies against human immunodeficiency virus (HIV) is now used routinely in order to minimize transfusion-associated HIV infections. The assay principle most widely applied for screening is the indirect immunoassay using solid-phasebound purified HIV antigen (11, 12) . The well-recognized occurrence of false-positive reactions in this kind of assay due to the presence of cell-specified contaminants in the antigen has made confirmatory examination of reactive specimens, preferably by using an alternative type of assay, a necessary part of the diagnostic routine (5, 13, 14) .
Assays commonly used for confirmatory purposes include Western (immuno-) blot (WB), radioimmunoprecipitation, and indirect immunofluorescence. WB is presently the most widely applied method for confirmatory serology (4) . Unlike the conventional indirect assay, WB is capable of differentiating the antibody response into reactivities against individual viral polypeptides, which allows positive sera with HIV-characteristic band patterns to be identified with high specificity. In contrast, the specificity of single-band responses (predominantly corresponding to the position of p24) cannot be judged conclusively by WB (1, 2) . In such cases the serological diagnosis depends on the possible appearance of additional HIV-characteristic bands in WB performed on subsequent samples. The definitive serological answer may thus be delayed for several weeks to months.
There is therefore a need for alternative methods of high specificity to aid in the confirmatory diagnosis of HIV infection. Inhibition immunoassays might be of value in this respect because in this kind of assay the specificity depends on the indicator antibodies, the purity of which can be secured by simple immunochemical procedures, and not on the purity of the viral antigen. This paper describes an inhibition enzyme-linked immunosorbent assay (ELISA) for detection of HIV-specific antibodies and presents data concerning its diagnostic value with * Corresponding author. sera giving equivocal reactions in indirect ELISA and/or WB.
MATERIALS AND METHODS
Cell and virus propagation. The CDC 451 strain of HIV-1 was propagated in cloned HUT-78 cells (Clone 6D5 from the Centers for Disease Control [3] ). The persistently infected cells were cultured in screw-cap flasks (Catalog no. 156502; Nunc, Roskilde, Denmark) at 36°C in 5% CO, using RPMI 1640 supplemented with antibiotics and 10% fetal calf serum. Half of the medium was changed twice weekly, and the doubling time of the cells was 1 to 2 weeks. The cell line was maintained at a density of approximately 5 x 105 celîs per ml, with a ratio of live to dead cells of about 6:4. The amount of virus released into the medium was monitored by a biotin-avidin-potentiated double-antibody sandwich ELISA for antigen detection (8) and centrifuged for 4 h in an AH629 rotor at 100,000 x g at 4°C through 5 ml of 20% (wt/vol) sucrose. The pellet was suspended in NET buffer with 1% (vol/vol) Triton X-100-1 mM phenylmethylsulfonyl fluoride-0.05% (wt/vol) sodium azide at 1:2,000 the original volume, incubated at 56°C for 1 h, and sonicated. The purified HIV antigen was kept at -80°C. WB analysis of purified antigen preparations using known anti-HIV-positive sera revealed the presence of all of the major antigens specified by the viral genome.
Anti-HIV IgG. Immunoglobulin G (IgG) was purified from a pool of four human serum samples with exceptionally high titers of IgG against HIV (above 100,000 by indirect ELISA) and with strong reactivity in WB against all major viral bands. Purification was done by ion-exchange chromatography on DEAE-Tris acryl M (LKB Instruments, Inc., Rockville, Md.) in 25 mM Tris, pH 8.8-35 mM NaCl; affinity chromatography was then performed on protein A-Sepharose CL 4B (Pharmacia-LKB, Uppsala, Sweden) as previously described (9) . Purified IgG was concentrated by negative-pressure ultrafiltration followed by dialysis against phosphate-buffered saline, pH 7.4, and adjusted to a protein concentration of 5 mg per ml. A part of the purified IgG was labeled with biotin as previously described (9 (12) . In the present study, 100 pd of purified HIV antigen diluted 1:2,000 in carbonate buffer, pH 9.6, was added to each well of a microtest plate (Immunoplate t; Nunc) and incubated at 4°C overnight. The washing procedure and composition of wash buffer and dilution buffer was identical to the inhibition assay described above.
Serum was added in 1:100 dilution in duplicate (100 pi in each well) and incubated for 2 h at room temperature. After a wash, 100 p1i of horseradish peroxidase-conjugated rabbit anti-human IgG (catalog no. P 214; Dakopatts, Copenhagen, Denmark) was added to each well and incubated for 1 h at room temperature. After a final wash, enzyme activity was detected as described above. A panel of 10 negative serum samples was included in every plate, and serum samples with OD readings >3 times the average OD value of the negative panel were considered positive for HIV antibodies, while serum samples with OD values c3 times the mean negative OD value were deemed negative.
Immunoblot assay. Purified HIV-1 grown in H9 cells was obtained from Du Pont Co., Wilmington, Del. The WB was performed as previously described (6) . Briefly, the viral antigen was heated to 100°C for 2 min in sample buffer containing 2% sodium dodecyl sulfate and 5% 2-mercaptoethanol and submitted to sodium dodecyl sulfate-polyacrylamide gel electrophoresis in a 5 to 15% gradient gel. The proteins were electroblotted onto nitrocellulose sheets which were cut into strips after being blotted with 2% Tween 20. Serum samples diluted 1:500 in Tris hydrochloride, pH 10.2-0.5 M NaCl-0.1% Tween 20-0.5% normal rabbit serum were incubated with the strips overnight at room temperature. Horseradish peroxidase-conjugated rabbit anti-human IgG A reagent combination with a low antigen dose was selected in order to provide optimal conditions for detection of the HIV antigen-combining activity elicited by antibody-positive sera.
The 180 serum samples which were positive in indirect ELISA and negative in WB all gave a negative result in the inhibition ELISA (Fig. 1) . The 44 serum samples which were positive in indirect ELISA and dubious in WB (single p24 reaction) were separated into two groups by the inhibition ELISA (31 were negative and 12 were positive). One serum sample gave a reaction equal to the cutoff level. The 10 ELISA-negative serum samples giving dubious reactions in WB were al negative in the inhibition assay. Table 1 shows that 7 of the 782 unselected donor serum samples reacted positively in indirect ELISA, and one of these serum samples was also positive in the inhibition test. This single specimen was confirmed positive in WB, while the remaining six ELISA-positive serum samples were found to be negative. 
DISCUSSION
It is well recognized that inhibition immunoassays are superior to indirect ELISA in terms of specificity. The reason is that the specificity of the inhibition assay is based on the subsequent detection of the antigen introduced into the assay, which means that only epitope specificities identical to those of the detecting antibody preparation are registered.
One of the drawbacks on the indirect ELISA is that antibodies to cellular contaminants in the purified HIV antigen preparation can cause false-positive reactions (5, 14) . We have previously shown that serum antibodies to nonviral epitopes present in the antigen preparation used in an inhibition assay do not cause inhibition (9) .
The inhibition assay might, at least in theory, generate false-negative results due to nonspecific binding of capture antibodies to the detecting antibodies. Rheumatoid factor in the serum being tested might cause this reaction. We have previously shown that the use of biotinylated detecting antibodies in this kind of assay greatly reduces this possibility (9) . The reason for this is that biotinylated antibodies are less denatured than antibodies coupled directly to enzyme molecules and because the biotin-avidin amplification makes it possible to use very small amounts of detecting antibodies.
The presence of HIV antigen in the serum sample under test likewise links the detecting antibodies to the capture antibodies. The inclusion of a control well without antigen in this kind of assay is therefore of paramount importance, as it reveals such reactions. In the present study, none of the 1,016 serum samples tested displayed control well reactions, but sera with a known high content of HIV antigen did give readings up to OD values of 0.5 in the control well. The same reaction occurred in the test well (but was unseen) and counteracted the inhibition caused by the coexisting HIV antibodies (unpublished observations).
It has previously been shown that inhibition assays based on extracellular HIV-antigen and using polyclonal capture and detecting antibodies of human origin first and foremost detect antibodies against the major core protein (p24) of HIV (7) . In accordance with this, some of our sera giving single p24 reactions in WB were positive in the competitive assay with 100% inhibition. Conversely, sera containing little or no detectable antibody reactivity to p24, as is often seen in the later stages of HIV infection (10) , may give false-negative results in this kind of assay (7) .
Apart from specificity, the most important quality of the assay is therefore its ability to distinguish clearly between positive and negative sera. The 234 serum samples tested were "trouble serum samples-selected from the Danish blood bank screening of approximately 250,000 donations. and only one of these serum samples gave an indeterminate reaction in the inhibition assay.
Some of the WB-dubious sera (p24) exhibited complete inhibition, and some were clearly negative in the competitive assay. Most likely the positive sera contained antibodies against virus-specific p24. This was confirmed by demonstration of seroconversion in five cases from which serum samples drawn later could be obtained. The nature of the WB p24 reactions of sera giving negative reactions in the inhibition assay remains to be determined. 
